SecBot SecBot
8-K ·Filed Mar 5, 2026

BVS

Bioventus Inc.
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0001665988-26-000010
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong organic growth, improved profitability, and robust 2026 guidance suggest Bioventus is successfully executing its strategy. Traders should monitor the execution of this guidance, particularly the margin expansion and cash flow generation, which could support further stock appreciation.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.10
T+0 close · Mar 5, 2026 · via day close
Latest settled
−12.86%
T+60 · $7.93
Vs SPY
−24.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $9.10entry
  2. T+1 · 9mo ago −7.58%α −6.27% · $8.41
  3. T+5 · 8mo ago −5.49%α −3.26% · $8.60
  4. T+20 · 8mo ago −1.43%α +2.36% · $8.97
  5. T+60 · 6mo ago −12.86%α −24.16% · $7.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bioventus reported strong Q4 2025 results with $157.9M revenue (2.8% YoY growth, 10% organic growth) and GAAP EPS of $0.21, reversing a prior-year loss. The company achieved $38M in operating cash flow (97% increase) and issued 2026 guidance projecting $600-610M revenue and $0.73-0.77 Adjusted EPS, indicating continued growth momentum.

Key Financial Metrics

Revenue
$157.9M
+2.8% YoY
Adj. EPS
$0.24
GAAP: $0.21
Guidance
$600M-$610M
raised
Gross Margin
68.9%

Key Facts

  • Q4 revenue: $157.9M (+2.8% YoY, +10% organic)
  • Q4 GAAP EPS: $0.21 (vs. $0.00 prior year)
  • Q4 cash from operations: $38M (+97% YoY)
  • 2026 guidance: $600-610M revenue (+6-7%), $0.73-0.77 Adjusted EPS (+7-13%)
  • Full-year 2025 revenue: $568.1M (-0.9% YoY, +7.5% organic)

Financial Impact

Q4 revenue increased by $4.3M YoY, with 2026 revenue guidance projecting $32-42M growth over 2025. Adjusted EPS is expected to grow by $0.05-0.09 in 2026.

revenueepscashFlow

Segment Breakdown

SegmentRevenueGrowth
Pain Treatments$79.7M+15.1%
Surgical Solutions$55.5M+3.4%
Restorative Therapies$22.7M-26.0%

Risk Factors

  • The prior-year revenue comparison was affected by the divestiture of the Advanced Rehabilitation Business, which could distort YoY growth metrics.
  • The company's Adjusted EPS guidance increase (7-13%) is modest compared to the significant improvement from 2024 to 2025 (from -$0.56 to $0.68).

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001665988-26-000010
Document: bvs-20260305.htm0001665988-26-000010
Document: 0001665988-26-000010-index-headers.html0001665988-26-000010
Document: 0001665988-26-000010-index.html0001665988-26-000010
Document: 0001665988-26-000010.txt0001665988-26-000010

Track record

18 reports on BVS

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
  2. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
  3. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  4. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
  6. Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
  7. Aug 5, 202614w ago 8-K Bullish 7/10 No price data
  8. Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
  10. Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026